PDL BioPharma, Inc. acquires, manages, and commercializes commercial stage pharmaceutical assets and late clinical stage pharmaceutical products in North America, Europe, Asia, and internationally.
No risks detected for PDLI from our risk checks.
Adequate balance sheet with moderate growth potential.
Share Price & News
How has PDL BioPharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PDLI has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: PDLI underperformed the US Biotechs industry which returned 24.5% over the past year.
Return vs Market: PDLI matched the US Market which returned 12.5% over the past year.
Price Volatility Vs. Market
How volatile is PDL BioPharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StDoes The PDL BioPharma, Inc. (NASDAQ:PDLI) Share Price Tend To Follow The Market?
2 months ago | Simply Wall StThe PDL BioPharma (NASDAQ:PDLI) Share Price Is Up 52% And Shareholders Are Holding On
3 months ago | Simply Wall StIs PDL BioPharma, Inc. (NASDAQ:PDLI) Worth US$2.8 Based On Its Intrinsic Value?
Is PDL BioPharma undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: PDLI ($3.18) is trading above our estimate of fair value ($0.12)
Significantly Below Fair Value: PDLI is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: PDLI is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: PDLI is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PDLI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PDLI is good value based on its PB Ratio (0.7x) compared to the US Biotechs industry average (3.3x).
How is PDL BioPharma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PDLI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: PDLI is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: PDLI's is expected to become profitable in the next 3 years.
Revenue vs Market: PDLI's revenue is expected to decline over the next 3 years (-1.6% per year).
High Growth Revenue: PDLI's revenue is forecast to decline over the next 3 years (-1.6% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PDLI's Return on Equity is forecast to be high in 3 years time
How has PDL BioPharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PDLI is currently unprofitable.
Growing Profit Margin: PDLI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PDLI is unprofitable, and losses have increased over the past 5 years at a rate of 66.9% per year.
Accelerating Growth: Unable to compare PDLI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PDLI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-22.5%).
Return on Equity
High ROE: PDLI has a negative Return on Equity (-17%), as it is currently unprofitable.
How is PDL BioPharma's financial position?
Financial Position Analysis
Short Term Liabilities: PDLI's short term assets ($551.3M) exceed its short term liabilities ($41.7M).
Long Term Liabilities: PDLI's short term assets ($551.3M) exceed its long term liabilities ($64.9M).
Debt to Equity History and Analysis
Debt Level: PDLI's debt to equity ratio (2.2%) is considered satisfactory.
Reducing Debt: PDLI's debt to equity ratio has reduced from 116.4% to 2.2% over the past 5 years.
Debt Coverage: PDLI's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if PDLI's interest payments on its debt are well covered by EBIT.
What is PDL BioPharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PDLI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PDLI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PDLI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PDLI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: PDLI is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PDLI's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dominique Monnet (59 yo)
Mr. Dominique P. Monnet serves as Member of Advisory Board at Antibe Therapeutics Inc. since October 2018. Mr. Monnet has been President at PDL BioPharma, Inc. since September 11, 2017 and has been its Chi ...
CEO Compensation Analysis
Compensation vs Market: Dominique's total compensation ($USD6.70M) is above average for companies of similar size in the US market ($USD2.06M).
Compensation vs Earnings: Dominique's compensation has increased whilst the company is unprofitable.
|CEO, President & Director||1.67yrs||US$6.70m||1.08% |
|VP, CFO & Chief Accounting Officer||0.75yr||US$814.14k||0.20% |
|VP, General Counsel & Secretary||11.5yrs||US$2.45m||0.54% |
|Deputy General Counsel & Assistant Secretary||3.58yrs||no data||no data|
Experienced Management: PDLI's management team is considered experienced (2.6 years average tenure).
|CEO, President & Director||1.67yrs||US$6.70m||1.08% |
|Independent Director||6.42yrs||US$282.50k||0.19% |
|Independent Director||11.83yrs||US$302.50k||0.23% |
|Independent Chairperson of the Board||0.58yr||US$270.04k||0.056% |
|Independent Director||0.50yr||no data||0.0067% |
|Independent Director||1.17yrs||US$202.78k||0.044% |
Experienced Board: PDLI's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
PDL BioPharma, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: PDL BioPharma, Inc.
- Ticker: PDLI
- Exchange: NasdaqGS
- Founded: 1986
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$362.344m
- Shares outstanding: 113.94m
- Website: https://www.pdl.com
Number of Employees
- PDL BioPharma, Inc.
- 932 Southwood Boulevard
- Incline Village
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PDLI||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Jan 1992|
|PDL||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jan 1992|
PDL BioPharma, Inc. acquires, manages, and commercializes commercial stage pharmaceutical assets and late clinical stage pharmaceutical products in North America, Europe, Asia, and internationally. The com ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/08/03 00:29|
|End of Day Share Price||2020/07/31 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.